S. Tourt-Uhlig

发表

Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.

R. McLendon, A. Friedman, J. Provenzale, 2001, Neuro-oncology.

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

R. McLendon, A. Friedman, M. Dolan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

A. Friedman, D. Bigner, J. Provenzale, 2004, Neuro-oncology.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2014, Investigational New Drugs.

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

A. Friedman, D. Bigner, J. Provenzale, 2004, Neuro-oncology.

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

R. McLendon, A. Friedman, D. Bigner, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma 1

A. Friedman, D. Bigner, J. Provenzale, 2004 .

Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.

R. McLendon, A. Friedman, J. Provenzale, 2001, Neuro-oncology.

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

R. McLendon, A. Friedman, M. Dolan, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of irinotecan ( CPT-11 ) in children with high-risk malignant brain tumors : The Duke experience 1

R. McLendon, A. Friedman, J. Eastwood, 2005 .

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

R. McLendon, A. Friedman, J. Eastwood, 2002, Neuro-oncology.

Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

M. Berger, R. McLendon, A. Friedman, 2003, Journal of Neuro-Oncology.

Phase II study of carboplatin in children with progressive low-grade gliomas.

H. Friedman, D. Reardon, D. Ashley, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of gefitinib in recurrent glioblastoma.

Allan H Friedman, R. McLendon, A. Friedman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

R. McLendon, A. Friedman, D. Bigner, 2006, Clinical Cancer Research.

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Allan H Friedman, James M Provenzale, R. McLendon, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a reevaluation of cardiovascular outcomes in the RECORD trial.

Robert Bigelow, J. McMurray, L. Newby, 2013, American heart journal.

Phase I I T rial o f T emozolomide i n P atients W ith P rogressive Low-Grade G lioma

R. McLendon, A. Friedman, D. Bigner, 2003 .

Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial

K. Anstrom, J. Alexander, S. Goodman, 2016, American heart journal.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

H. Hurwitz, J. Bendell, M. Morse, 2012, Journal of Clinical Oncology.

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.

Robert Bigelow, J. McMurray, L. Newby, 2013, American heart journal.

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

R. McLendon, A. Friedman, J. Eastwood, 2002 .